ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1452

Inflammatory Markers and Left Ventricular Dysfunction in Systemic Lupus Erythematosus (SLE)
Abstract Number: 0301

Inflammatory Myopathies and Their Relationship with Cancer in a Colombian Cohort
Abstract Number: 1766

Inflammatory Priming of the Joints via Pre-activation of Macrophages by Anti-MAA Antibodies in Rheumatoid Arthritis
Abstract Number: 0442

Infliximab Clearance a Predictive Factor of Pharmacokinetic Origin in Relation to Suboptimal Pharmacokinetics and Immunogenicity in United States Based Rheumatology Practices
Abstract Number: 2499

Influence of Adiposity on Physical Function, Physical Activity, and Self-Reported Symptom Severity for Individuals with Arthritis Prior to Beginning a Physical Activity Promotion Intervention
Abstract Number: 2417

Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study
Abstract Number: 1316

Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis
Abstract Number: 1847

Influence of Seasonal Changes on Adherence in Rheumatoid Arthritis Patients
Abstract Number: 0779

Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)
Abstract Number: 0189

Influence of Social Support on Systemic Lupus Erythematosus (SLE) Outcomes in a Health Disparity Population
Abstract Number: 1978

Infrapatellar Fat Pad Size and Subcutaneous Fat in Knee Osteoarthritis Radiographic Progression: Data from the Osteoarthritis Initiative
Abstract Number: 1047

Infrared Thermography Imaging Discriminates Between Inflamed and Non-inflamed Joints
Abstract Number: 0838

Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections
Abstract Number: 0332

Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis
Abstract Number: 0797

Innate Lymphoid Cells Enhance Development of CD4+ T-cell Driven Autoimmune Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].